Article
Gastroenterology & Hepatology
Peihao Liu, Yuwei Zhang, Chenxi Tang, Li Cen, Yishu Chen, Sha Li, Xueyang Chen, Mengli Yu, Jie Zhang, Xiaofen Zhang, Hang Zeng, Chengfu Xu, Chaohui Yu
Summary: DDX3x plays a potential role in the progression of NAFLD by affecting the mTORC1 signaling pathway. It may be a potential target for the treatment of NAFLD.
LIVER INTERNATIONAL
(2022)
Review
Biochemistry & Molecular Biology
Hao Xu, Lin Wang
Summary: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and may progress to non-alcoholic steatohepatitis (NASH) or liver cancer. Studies have shown that the Notch signaling pathway plays a key role in the development of NAFLD.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Yajing You, Chenxi Liu, Tiantian Liu, Miaomiao Tian, Nijin Wu, Zhen Yu, Fenglin Zhao, Jianni Qi, Qiang Zhu
Summary: This study reveals the crucial role of FNDC3B in protecting against hepatic steatosis and ferroptosis in response to chronic alcohol consumption. Our findings suggest that FNDC3B could be a potential therapeutic target for ALD.
FREE RADICAL BIOLOGY AND MEDICINE
(2022)
Article
Biology
Mengyao Wu, Tak-Ho Lo, Liping Li, Jia Sun, Chujun Deng, Ka-Ying Chan, Xiang Li, Steve Ting-Yuan Yeh, Jimmy Tsz Hang Lee, Pauline Po Yee Lui, Aimin Xu, Chi-Ming Wong
Summary: This study found that adhesion G protein-coupled receptor F1 (Adgrf1) regulates hepatic lipid metabolism by controlling the expression of stearoyl-coA desaturase 1 (Scd1). The downregulation of Adgrf1 expression in the livers of obese subjects may serve as a protective mechanism to prevent the excessive accumulation of fat. These findings not only reveal a new mechanism for the progression of non-alcoholic fatty liver disease (NAFLD), but also propose a novel therapeutic approach to combat NAFLD by targeting Adgrf1.
Review
Physiology
Chunqiu Fang, Jianheng Pan, Ning Qu, Yuting Lei, Jiajun Han, Jingzhou Zhang, Dong Han
Summary: Lipid metabolism disorders are the primary causes for various liver diseases, and the activation of the AMPK signaling pathway plays an important role in ameliorating these disorders. AMPK activation can alleviate fatty liver disease caused by alcohol, insulin resistance, type 2 diabetes, and obesity. Natural AMPK agonists can regulate lipid metabolism, inflammation, and oxidative stress in hepatocytes, thereby regulating fatty liver disease.
FRONTIERS IN PHYSIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Marziyeh Anari, Magdalene K. Montgomery
Summary: Mammalian cells contain a wide variety of glycerophospholipid species, with phosphatidylserine (PS) playing a crucial role in various physiological processes. PS is involved in apoptosis, blood clotting, cancer pathogenesis, and muscle and brain function. Recent studies have focused on the role of hepatic PS in non-alcoholic fatty liver disease (NAFLD) and liver cancer progression. This review provides a comprehensive overview of hepatic phospholipid metabolism and delves into the metabolism of PS in advanced liver disease.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Veterinary Sciences
Lihui Zhu, Rongrong Liao, Jiwen Huang, Huaxiang Yan, Changfeng Xiao, Yunzhou Yang, Huiying Wang, Changsuo Yang
Summary: This study discovered 12 dysregulated miRNAs between fatty livers and normal livers in laying hens. Functional enrichment analysis showed the potential impacts of these dysregulated miRNAs on lipid metabolism. Specifically, up-regulation of the miR-216/miR-217 cluster induced lipid accumulation in FFA-induced liver cells and directly targeted genes in the PPAR/SREBP pathway.
FRONTIERS IN VETERINARY SCIENCE
(2022)
Article
Endocrinology & Metabolism
Xingchun Wang, Bangfeng Zhao, Hang Sun, Hui You, Shen Qu
Summary: This study aimed to evaluate the effects of sitagliptin on intrahepatic lipid (IHL) content in patients with nonalcoholic fatty liver disease (NAFLD). The results showed that sitagliptin improved glucose metabolism abnormalities but did not directly reduce IHL in patients with NAFLD.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Immunology
Jiayi Liu, Anding Wu, Jingjing Cai, Zhi-Gang She, Hongliang Li
Summary: NAFLD, the liver manifestation of metabolic syndrome, involves various factors such as metabolic disturbances, inflammation, and cell death. The intestinal-liver axis theory suggests a close relationship between changes in intestinal flora and the development of NAFLD, affecting pathways like energy metabolism to regulate the pathogenesis of NAFLD.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Gastroenterology & Hepatology
Cheng Chang, Huicong Li, Ruilin Zhang
Summary: Non-alcoholic fatty liver disease (NAFLD) is a growing metabolic disease worldwide. Zebrafish, with their genetic and metabolic similarity to mammals, as well as unique advantages such as high fecundity and optical transparency, have become an emerging model for studying liver and metabolic diseases. In this review, we summarize the tools and models used in zebrafish NAFLD research, including dietary feeding, chemical treatments, and genetic manipulations. We also discuss how zebrafish models contribute to our understanding of NAFLD pathogenesis, toxicology, and drug evaluation.
LIVER INTERNATIONAL
(2023)
Review
Biochemistry & Molecular Biology
Chia-Jung Liao, Po-Shuan Huang, Hui-Tzu Chien, Tzu-Kang Lin, Chau-Ting Yeh, Kwang-Huei Lin
Summary: The typical modern lifestyle contributes to the development of metabolic disorders. Thyroid hormones play an important role in liver lipid metabolism and have potential applications in the management of non-alcoholic fatty liver disease (NAFLD).
Article
Biochemistry & Molecular Biology
Chian-Jiun Liou, Shu-Ju Wu, Szu-Chuan Shen, Li-Chen Chen, Ya-Ling Chen, Wen-Chung Huang
Summary: Acacetin reduces lipid accumulation, improves hepatocyte steatosis, and regulates lipid metabolism and inflammation in obese mice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Hyejin Kim, Chaewon Park, Tae Hyun Kim
Summary: Non-alcoholic fatty liver disease (NAFLD) is a group of conditions characterized by excessive accumulation of lipids in the liver, resulting in serious hepatic manifestations. Despite its global prevalence and impact on liver disease, there is no approved medication for NAFLD treatment. Liver X receptors alpha/beta (LXRα and LXRβ) are key regulators of lipid homeostasis and play critical roles in metabolic processes. Dysregulated LXR signaling is strongly associated with NAFLD progression. Targeting LXRs may offer promising therapeutic strategies for NAFLD treatment. However, modulating LXR activity can have varying metabolic consequences depending on cell type. Understanding how LXRs integrate signaling pathways and regulate metabolic homeostasis in the liver may provide new insights into NAFLD and associated metabolic diseases.
Article
Medicine, Research & Experimental
Poliana C. Marinello, Paola S. Cella, Mayra T. J. Testa, Phillipe B. Guirro, Walison Augusto da Silva Brito, Camila S. Padilha, Alessandra L. Cecchini, Robin P. da Silva, Jose Alberto R. Duarte, Rafael Deminice
Summary: This study investigated the effects of creatine supplementation on the pathogenesis of non-alcoholic fatty liver disease and alcoholic liver disease. The results showed that creatine supplementation prevented high-fat diet-induced non-alcoholic fatty liver disease but exacerbated ethanol-induced alcoholic liver disease. The exacerbating effects may be related to oxidative stress and inflammation-mediated upregulation of ethanol metabolism.
Article
Food Science & Technology
Jae-Hyuk Byun, Ji Eun Shin, Yeung-Joon Choi, Se-Young Choung
Summary: TGPN significantly improved alcoholic fatty liver by decreasing liver index and lipid levels, increasing adiponectin level, and reducing liver fat accumulation. It activated AMP-activated protein kinase and its downstream pathway, promoting lipid metabolism and decreasing liver function markers, ultimately reducing liver cell damage.
INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY
(2021)